HBP — Helix Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- CA$41.36m
- CA$39.36m
- 15
- 15
- 47
- 14
Annual cashflow statement for Helix Biopharma, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.56 | -8.04 | -6.56 | -6.29 | -9.26 |
| Depreciation | |||||
| Non-Cash Items | -0.365 | -1.41 | 0.935 | 0.564 | 3.55 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.11 | -0.054 | -0.893 | 0.186 | 0.485 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -10.8 | -9.3 | -6.51 | -5.53 | -5.22 |
| Capital Expenditures | -0.016 | 0 | — | -0.01 | -0.014 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.72 | 2.02 | 0 | 0.005 | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 1.7 | 2.02 | 0 | -0.005 | -0.014 |
| Financing Cash Flow Items | 1.06 | 0 | — | 0.999 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 13.1 | 6.56 | 6.21 | 3.09 | 5.51 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.03 | -0.67 | -0.313 | -2.44 | 0.273 |